F605 in New Hampshire. Pick another state for the same tag.
Against expectation — 2025
New Hampshire cites F605 more often than its own record predicts
Versus expected share2.04×
2.04 times the share F605 takes of citations nationally.
Share of New Hampshire citations1.44%
Of every deficiency written in New Hampshire in 2025, this is the portion that was F605.
New Hampshire1.44%
National0.70%
Share of all citations that were F605.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What New Hampshire surveyors wrote
F605 findings written in New Hampshire, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedAugust 12, 2026
Based on interview and record review, the facility failed to provide a rationale to extend a PRN (as needed) anti-anxiety medication beyond the 14 days when prescribed for 1 of 1 resident reviewed for behavioral-emotional in a final sample of 13 residents (Resident identifier is #10).Findings include:Review on 8/11/26 of Resident #10's physician orders revealed an order, dated 6/26/26, for Ativan 2mg (milligrams)/ml (milliliter) Give 0.5ml sublingually every 2 hours as needed for Anxiety or Dyspnea with no specified duration of the PRN order.Review on 8/11/26 of Resident #10's physician and provider notes revealed that there was no documentation for a rationale to extend the PRN Ativan. Interview on 8/12/26 at approximately 8:30 a.m. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction